GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $5.80 Average Price Target from Brokerages

Key Points

• GoodRx Holdings, Inc. has received a consensus rating of "Hold" from analysts, with an average price target of $5.80.
• In its latest earnings report, GoodRx reported $0.09 earnings per share, missing consensus estimates, and showed a 1.2% year-over-year increase in revenue compared to the same quarter last year.
• Major shareholder Spectrum recently sold 10,677 shares of GoodRx stock at an average price of $4.80, revealing ongoing insider activity as institutional investors adjust their positions.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) has been given a consensus recommendation of "Hold" by the eleven analysts that are currently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $5.80.

A number of research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a $6.00 price objective on shares of GoodRx in a research note on Monday, August 11th. The Goldman Sachs Group reduced their price objective on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Raymond James Financial lowered shares of GoodRx from a "strong-buy" rating to an "outperform" rating in a research note on Friday, August 8th. Finally, UBS Group reduced their price objective on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a research note on Tuesday, May 13th.

Insider Activity at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business's stock in a transaction on Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total transaction of $51,249.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.17% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Headlands Technologies LLC grew its position in shares of GoodRx by 155.7% during the 2nd quarter. Headlands Technologies LLC now owns 37,914 shares of the company's stock valued at $189,000 after purchasing an additional 23,084 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of GoodRx by 202.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company's stock valued at $56,000 after purchasing an additional 7,580 shares in the last quarter. Sugar Maple Asset Management LLC purchased a new position in shares of GoodRx during the 2nd quarter valued at $189,000. State of Tennessee Department of Treasury purchased a new position in shares of GoodRx during the 2nd quarter valued at $145,000. Finally, Lazard Asset Management LLC grew its position in GoodRx by 43.6% in the second quarter. Lazard Asset Management LLC now owns 17,142 shares of the company's stock worth $85,000 after acquiring an additional 5,201 shares in the last quarter. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

GoodRx Stock Performance

Shares of NASDAQ:GDRX traded down $0.01 during mid-day trading on Friday, reaching $4.29. The company had a trading volume of 1,106,925 shares, compared to its average volume of 6,055,755. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.75. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of 42.90, a PEG ratio of 1.90 and a beta of 1.23. The company's 50-day moving average price is $4.54 and its 200-day moving average price is $4.47. GoodRx has a one year low of $3.31 and a one year high of $8.16.

GoodRx (NASDAQ:GDRX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). GoodRx had a return on equity of 8.86% and a net margin of 4.33%.The company had revenue of $203.07 million during the quarter, compared to the consensus estimate of $205.72 million. During the same period last year, the firm posted $0.08 EPS. The company's revenue for the quarter was up 1.2% compared to the same quarter last year. As a group, equities research analysts anticipate that GoodRx will post 0.13 EPS for the current fiscal year.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.